The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | A Phase I/II study of acalabrutinib, venetoclax, & obinutuzumab in R/R and treatment-naive MCL
Austin Kim, MD, Dana-Farber Cancer Institute, Boston, MA, presents the results of the MAVO study (NCT04855695), a Phase I/II trial investigating the combination of acalabrutinib, venetoclax, and obinutuzumab (AVO) in patients with relapsed/refractory (R/R) and previously untreated mantle cell lymphoma (MCL). This combination was explored in three cohorts of patients, with highly encouraging safety and efficacy data. Dr Kim also notes that the study’s findings support the potential for time-limited therapy with this triplet regimen in treatment-naive patients, as a significant proportion of individuals were able to discontinue acalabrutinib and venetoclax after achieving undetectable measurable residual disease complete remission (MRD-CR). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
